In vivo verification of treatment source dwell times in brachytherapy of postoperative endometrial carcinoma: a feasibility study

dc.contributor.author
Herreros, Antonio
dc.contributor.author
Pérez Calatayud, José
dc.contributor.author
Ballester, Facundo
dc.contributor.author
Barrera Gómez, José
dc.contributor.author
Abellana Sangrà, Rosa Mari
dc.contributor.author
Melo, Joana
dc.contributor.author
Moutinho, Luis
dc.contributor.author
Tagliaferri, L.
dc.contributor.author
Rovirosa Casino, Angeles
dc.date.issued
2023-02-13T13:25:16Z
dc.date.issued
2023-02-13T13:25:16Z
dc.date.issued
2022-05-31
dc.date.issued
2023-02-13T13:25:16Z
dc.identifier
2075-4426
dc.identifier
https://hdl.handle.net/2445/193520
dc.identifier
723843
dc.identifier
35743696
dc.description.abstract
Background: In brachytherapy, there are still many manual procedures that can cause adverse events which can be detected with in vivo dosimetry systems. Plastic scintillator dosimeters (PSD) have interesting properties to achieve this objective such as real-time reading, linearity, repeatability, and small size to fit inside brachytherapy catheters. The purpose of this study was to evaluate the performance of a PSD in postoperative endometrial brachytherapy in terms of source dwell time accuracy. Methods: Measurements were carried out in a PMMA phantom to characterise the PSD. Patient measurements in 121 dwell positions were analysed to obtain the differences between planned and measured dwell times. Results: The repeatability test showed a relative standard deviation below 1% for the measured dwell times. The relative standard deviation of the PSD sensitivity with accumulated absorbed dose was lower than 1.2%. The equipment operated linearly in total counts with respect to absorbed dose and also in count rate versus absorbed dose rate. The mean (standard deviation) of the absolute differences between planned and measured dwell times in patient treatments was 0.0 (0.2) seconds. Conclusions: The PSD system is useful as a quality assurance tool for brachytherapy treatments.
dc.format
13 p.
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
MDPI
dc.relation
Reproducció del document publicat a: https://doi.org/10.3390/jpm12060911
dc.relation
Journal of Personalized Medicine, 2022, vol. 12, num. 6
dc.relation
https://doi.org/10.3390/jpm12060911
dc.rights
cc-by (c) Herreros, Antonio et al., 2022
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Fonaments Clínics)
dc.subject
Càncer d'endometri
dc.subject
Braquiteràpia
dc.subject
Cura postoperatòria
dc.subject
Càncer ginecològic
dc.subject
Estudis de viabilitat
dc.subject
Endometrial cancer
dc.subject
Radioisotope brachytherapy
dc.subject
Postoperative care
dc.subject
Gynecologic cancer
dc.subject
Feasibility studies
dc.title
In vivo verification of treatment source dwell times in brachytherapy of postoperative endometrial carcinoma: a feasibility study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)